| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/24/2012 | US20120129758 Muscle function enhancing peptide |
| 05/24/2012 | US20120129757 Compositions and methods for promoting vascular barrier function and treating pulonary fibrosis |
| 05/24/2012 | US20120129184 Systemic carnitine deficiency gene and uses thereof |
| 05/24/2012 | US20120128782 Multicomponent Degradable Cationic Polymers |
| 05/24/2012 | US20120128779 Process for producing protein microparticles |
| 05/24/2012 | US20120128777 Compositions containing lipid micro- or nanoparticles for the enhancement of the dermal action of solid particles |
| 05/24/2012 | US20120128774 Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix |
| 05/24/2012 | US20120128767 Therapeutic calcium phosphate particles and methods of making and using same |
| 05/24/2012 | US20120128763 Lubricant for the ocular surface |
| 05/24/2012 | US20120128758 Formulation for inducing broadly reactive neutralizing anti-hiv antibodies |
| 05/24/2012 | US20120128756 Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof |
| 05/24/2012 | US20120128752 Multi-phase microparticles and method of manufacturing multi-phase microparticles |
| 05/24/2012 | US20120128747 Core-shell material, method for preparing same, and use thereof for the thermostimulated generation of substances of interest |
| 05/24/2012 | US20120128727 Bacterial expression of an artificial gene for the production of crm197 and its derivatives |
| 05/24/2012 | US20120128725 Detection/measurement of malaria infection disease utilizing natural immunity by hemozoin induction, screening of preventative or therapeutic medicine for malaria infection disease, and regulation of natural immunity induction |
| 05/24/2012 | US20120128721 Schistosoma vaccine |
| 05/24/2012 | US20120128707 Streptococcus pneumoniae proteins and nucleic acids |
| 05/24/2012 | US20120128705 C6orf167 peptides and vaccines containing the same |
| 05/24/2012 | US20120128701 Compositions and methods for the removal of biofilms |
| 05/24/2012 | US20120128700 Constructs for delivery of therapeutic agents to neuronal cells |
| 05/24/2012 | US20120128696 Methods for detecting and inhibiting angiogenesis |
| 05/24/2012 | US20120128695 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof |
| 05/24/2012 | US20120128683 Autism treatment |
| 05/24/2012 | US20120128682 Apolipoprotein l- i variants and their use |
| 05/24/2012 | US20120128677 Pancreatic cancer targets and uses thereof |
| 05/24/2012 | US20120128673 Modulation of pilr receptors to treat microbial infections |
| 05/24/2012 | US20120128670 mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY |
| 05/24/2012 | US20120128659 Agents capable of downregulating an msf-a - dependent hif-1alpha and use thereof in cancer treatment |
| 05/24/2012 | US20120128658 Rage g82s-related methods and compositions for treating inflammatory disorders |
| 05/24/2012 | US20120128657 Synthetic macrocyclic compounds and methods for treating cancer |
| 05/24/2012 | US20120128654 Allantoin Administration for the Treatment of Neurodegenerative Disease and Neurotrauma |
| 05/24/2012 | US20120128653 Process for making dry and stable hemostatic compositions |
| 05/24/2012 | US20120128652 Endolysin plyp40 |
| 05/24/2012 | US20120128651 Acute lymphoblastic leukemia (all) biomarkers |
| 05/24/2012 | US20120128650 Extended acting oxygen generating composition for treating microbial infections |
| 05/24/2012 | US20120128649 Modified non-cytotoxic proteases |
| 05/24/2012 | US20120128647 Delivery of compounds with rehydrated blood cells |
| 05/24/2012 | US20120128646 Methods and compositions for the treatment of autoimmune disease |
| 05/24/2012 | US20120128630 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharamaceutical composition thereof and their therapeutic use |
| 05/24/2012 | US20120128629 Method of labelling interferons with peg |
| 05/24/2012 | US20120128628 COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION (as amended) |
| 05/24/2012 | US20120128627 Il-17 homologous polypeptides and therapeutic uses thereof |
| 05/24/2012 | US20120128626 Anti-il-6 antibodies for the treatment of anemia |
| 05/24/2012 | US20120128625 Compounds, compositions, and methods for preventing metastasis of cancer cells |
| 05/24/2012 | US20120128624 Recombinant Human Albumin-Granulocyte Macrophage Colony Stimulating Factor Fusion Protein With Long-Lasting Biological Effects |
| 05/24/2012 | US20120128622 MRSA Bactericidal Topical Gel |
| 05/24/2012 | US20120128590 Nanoparticle delivery systems for membrane-integrating peptides |
| 05/24/2012 | US20120128587 Folate-targeted diagnostics and treatment |
| 05/24/2012 | US20120128586 Method for treating chronic lymphocytic leukemia |
| 05/24/2012 | US20120128581 Sincalide Formulations |
| 05/24/2012 | DE102010052941A1 Therapeutisches Protein Therapeutic protein |
| 05/24/2012 | DE102007048636B4 Marker zur Diagnose von Krebs Marker for diagnosing cancer |
| 05/24/2012 | CA2818610A1 Compositions and methods for hair growth |
| 05/24/2012 | CA2818253A1 Method for increasing neprilysin expression and activity |
| 05/24/2012 | CA2818166A1 Keratin compositions for treatment of bone deficiency or injury |
| 05/24/2012 | CA2818130A1 Orally administered pharmaceutical composition and preparation method thereof, for the prevention and treatment of irritable bowel syndrome, comprising an intestinal motility modifier and a-d-galactosidase |
| 05/24/2012 | CA2818129A1 Orally administered pharmaceutical composition for the treatment of irritable bowel syndrome, comprising an intestinal motility modifier, an agent that prevents gas retention, and digestive enzymes, and preparation method thereof |
| 05/24/2012 | CA2817996A1 Anti-inflammatory compositions |
| 05/24/2012 | CA2817846A1 Use of prolactin receptor antagonist and chemotherapeutic drug for treating ovarian cancer |
| 05/24/2012 | CA2817787A1 Composition comprising a peptide and an inhibitor of viral neuraminidase |
| 05/24/2012 | CA2817583A1 Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
| 05/24/2012 | CA2817537A1 Fgfr1 extracellular domain combination therapies |
| 05/24/2012 | CA2817362A1 Lipoyl compounds and their use for treating ischemic injury |
| 05/24/2012 | CA2817355A1 Methods and compositions for modulating pd1 |
| 05/24/2012 | CA2817096A1 A process for reduction and/or removal of fxi and fxia from solutions containing said coagulation factors |
| 05/24/2012 | CA2815044A1 Preparation and use of combination enzyme and gastrointestinal modulator delivery systems |
| 05/24/2012 | CA2813451A1 Methods of diagnosing and treating neurodegenerative diseases |
| 05/23/2012 | EP2455462A2 Lipase variants for pharmaceutical use |
| 05/23/2012 | EP2455461A2 Lipase variants for pharmaceutical use |
| 05/23/2012 | EP2455460A2 Lipase variants for pharmaceutical use |
| 05/23/2012 | EP2455459A2 Lipase variants for pharmaceutical use |
| 05/23/2012 | EP2455396A1 Sugar chain-added ailim extracellular domain and method for producing same |
| 05/23/2012 | EP2455105A2 Bombesin analogues |
| 05/23/2012 | EP2455099A1 Method of producing recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo |
| 05/23/2012 | EP2455098A1 New cyclic peptide compounds |
| 05/23/2012 | EP2455097A1 Proteoglycan-containing material |
| 05/23/2012 | EP2455087A2 Isolation and identification of heparan sulphate |
| 05/23/2012 | EP2455072A1 Controlled release formulations of octreotide |
| 05/23/2012 | EP2455065A1 Modified two-component gelation systems, methods of use and methods of manufacture |
| 05/23/2012 | EP2454282A1 Acylated glucagon analogues |
| 05/23/2012 | EP2454276A1 Therapeutic agents |
| 05/23/2012 | EP2454275A1 Process and system for obtaining botulinum neurotoxin |
| 05/23/2012 | EP2454273A2 A mechanism and method for regulating glycogen synthase kinase 3 (gsk3)-related kinases |
| 05/23/2012 | EP2453926A2 Peptides whose uptake in cells is controllable |
| 05/23/2012 | EP2453923A2 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
| 05/23/2012 | EP2453914A2 Antigen specific multi epitope -based anti-infective vaccines |
| 05/23/2012 | EP2453910A1 Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| 05/23/2012 | EP2453909A2 Antigen compositions and methods of inhibiting campylobacter jejuni bacterial infection and uses of the antigen compositions |
| 05/23/2012 | EP2453908A2 Bifunctional stapled polypeptides and uses thereof |
| 05/23/2012 | EP2453907A2 Reduced volume formulation of glatiramer acetate and methods of administration |
| 05/23/2012 | EP2453906A1 Methods of stimulating liver regeneration |
| 05/23/2012 | EP2453903A2 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
| 05/23/2012 | EP2453876A1 Hdl comprising a therapeutic agent and use in therapy |
| 05/23/2012 | EP2453838A2 Cosmetic use of lacritin-type polypeptides |
| 05/23/2012 | EP2170369B1 Viral latency model |
| 05/23/2012 | EP1959988B1 Use of bovine lactoferrin for treating destructive inflammation of mucous membrane |
| 05/23/2012 | EP1930017B1 Composition effective for prevention and treatment of adult disease |
| 05/23/2012 | EP1865976B1 Use of natriuretic peptide for treating heart failure |
| 05/23/2012 | EP1853290B1 Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates |
| 05/23/2012 | EP1848731B1 Antibiotic 107891, its factors, pharmaceutically acceptable salts and compositions, and use thereof |